This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analyst Reason No. 345 to Upgrade Biotech Stocks: Takeover Rumors in the Foreign Press!

By: Adam Feuerstein | 01/24/14 - 03:40 PM EST

Stocks in this article: ARIARCPTCELGTEVALLY

BMO Capital Markets biotech analyst Jim Birchenough is a big fan of upgrading his stocks based on unsubstantiated reports of takeover interest published in the foreign press. 

Take Ariad Pharmaceuticals (ARIA), which Birchenough upgraded Friday to outperform with a $14 price target in response to the Daily Mail article published Wednesday night speculating about an Eli Lilly (LLY) takeout offer of $20 per share.

The headline on Birchenough's Ariad notes reads, "Platform, Pipeline, Products Should Attract Pharma Interest; Upgrading to Outperform." Inside, he says:

ARIA shares saw strength yesterday following lay press reports of potential large pharma interest in acquiring the company (Daily Mail: Eli Lilly (LLY) hopes to buy Ariad Pharmaceuticals (ARIA) for as much as $20/share)... We believe there is significant value to be realized from ICLUSIG, AP26113, and the company's highly efficient drug discovery platform and believe that ARIA assets are likely to attract large pharma interest.

Hmm... Sounds familiar. And yes, it is!

Last October 16, Birchenough reiterated an outperform rating on Receptos  (RCPT) and raised his price target to $40. Why? I'll let him explain:
Receptos (RCPT) shares have been strong today on an article in an Israeli business publication suggesting that Celgene  (CELG) and Teva  (TEVA) are considering an acquisition of the company at valuations >$700M ("Teva, Celgene Bidding More Than $700M for Receptos," Calcalist). The focus of attention here is on RCPT's selective S1P1 modulator RPC-1063, in phase 2 development for multiple sclerosis (MS) and ulcerative colitis (UC), and approaching phase 3 initiation in MS by year-end 2013. While CELG "does not comment on market speculation" and wouldn't confirm interest in RCPT, the company acknowledged that it was open to expanding its focus in Inflammation and Immunology (I&I) beyond rheumatologic and dermatologic indications and does have the bandwidth to bring in outside mid-stage assets while continuing to increase operating margins.

Three months later, we're still waiting for Receptos to be acquired.

Ariad: Deja vu! 





Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs